Therapeutic Potential of Melatonin Ligands

References

• Audinot V., Mailliet F., Lahaye C., Bonnaud A., Le Gall A., Amosse A., Rodriguez M., Malpaux B., Delagrange P., Guillaumet G., Lesieur D., Lefoulon F., Galizzi J. P., Renard P., Boutin J. A. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2003; 367: 553–561
   PubMed Web of Science ®Google Scholar
• Boutin J. A., Audinot V., Ferry G., Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sci. 2005; 26: 412–419
   PubMed Web of Science ®Google Scholar
• Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T. C., Wu J. M., Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochem. 2004; 43: 1417–1426
   Google Scholar
• Dubocovich M. L. Pharmacology and function of melatonin receptors. FASEB J. 1988; 2: 2765–2773
   PubMed Web of Science ®Google Scholar
• Foster C. E., Bianchet M. A., Talalay P., Zhao Q., Amzel L. M. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochem. 1999; 38: 9881–9886
   PubMed Web of Science ®Google Scholar
• Fu Y., Buryanovskyy L., Zhang Z. Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem. Biophys. Res. Commun. 2005; 336: 332–338
   PubMedGoogle Scholar
• Harada S., Fujii C., Hayashi A., Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S‐transferase M1 and quinone oxidoreductases 1 and 2. Biochem. Biophys. Res. Commun. 2001; 288: 887–892
   PubMed Web of Science ®Google Scholar
• Harada S., Tachikawa H., Kawanishi Y. A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiatr. Genet. 2003; 13: 205–209
   PubMed Web of Science ®Google Scholar
• Herxheimer A., Petrie K. J. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst. Rev. 2002; CD001520
   PubMedGoogle Scholar
• Jin X., von Gall C., Pieschl R. L., Gribkoff V. K., Stehle J. H., Reppert S. M., Weaver D. R. Targeted disruption of the mouse Mel1b melatonin receptor. Mol. Cell. Biol. 2003; 23: 1054–1060
   PubMed Web of Science ®Google Scholar
• Liu C., Weaver D. R., Jin X., Shearman L. P., Pieschi R. L., Gribkoff V. K., Reppert S. M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997; 19: 91–102
   PubMed Web of Science ®Google Scholar
• Lagneux C., Joyeux M., Demenge P., Ribuot C., Godin‐Ribuot D. Protective effects of melatonin against ischemia‐reperfusion injury in the isolated rat heart. Life Sci. 2000; 66: 503–509
   PubMed Web of Science ®Google Scholar
• Long D. J., Iskander K., Gaikwad A., Arin M., Roop D. R., Knox R., Barrios R., Jaiswal A. K. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J. Biol. Chem. 2002; 277: 46131–46139
   PubMed Web of Science ®Google Scholar
• Lôo H., Hale A., D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5‐HT(2C) antagonist, in the treatment of major depressive disorder: a placebo‐controlled dose range study. Int. Clin. Psychopharmacol. 2002; 17: 239–247
   PubMed Web of Science ®Google Scholar
• Mailliet F., Ferry G., Vella F., Thiam K., Delagrange P., Boutin J. A. Organs from mice deleted for NRH:Quinone oxydoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett. 2004; 578: 116–120
   PubMed Web of Science ®Google Scholar
• Millan M. J., Gobert A., Lejeune F., Dekeyne A., Newman‐Tancredi A., Pasteau V., Rivet J. M., Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5‐hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003; 306: 954–964
   PubMed Web of Science ®Google Scholar
• Molinari E. J., North P. C., Dubocovich M. L. 2‐[125I]iodo‐5‐methoxycarbonylamino‐N‐acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites. Eur. J. Pharmacol. 1996; 301: 159–168
   PubMed Web of Science ®Google Scholar
• Montgomery S. A., Kennedy S. H., Burrows G. D., Lejoyeux M., Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double‐blind, placebo‐controlled discontinuation study. Int. Clin. Psychopharmacol. 2004; 19: 271–280
   PubMed Web of Science ®Google Scholar
• Nickelsen T., Samel A., Vejvoda M., Wenzel J., Smith B., Gerzer R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9 h time shift: results of a placebo‐controlled trial. Chronobiol. Int. 2002; 19: 915–936
   PubMed Web of Science ®Google Scholar
• Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J. M., Lefoulon F., Fauchere J. L., Delagrange P., Canet E., Boutin J. A. Identification of the melatonin‐binding Site MT3 as the Quinone Reductase 2. J. Biol. Chem. 2000; 275: 31311–31317
   PubMed Web of Science ®Google Scholar
• Osseni R. A., Rat P., Bogdan A., Warnet J. M., Touitou Y. Evidence of prooxidant and antioxydant action of melatonin on human liver cell line HepG2. Life Sci. 2000; 15: 387–399
   Google Scholar
• Papp M., Gruca P., Boyer P. A., Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacol. 2003; 28: 694–703
   PubMed Web of Science ®Google Scholar
• Paul P., Lahaye C., Delagrange P., Nicolas J. P., Canet E., Boutin J. A. Characterization of 2‐[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J. Pharmacol. Exp. Ther. 1999; 290: 334–340
   PubMed Web of Science ®Google Scholar
• Reiter R. J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991; 12: 151–180
   PubMed Web of Science ®Google Scholar
• Reiter R. J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow‐Walden L., Chuang J., Ortiz G. G., Acuna‐Castroviejo D. A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 1995; 18: 1–11
   PubMed Web of Science ®Google Scholar
• Wang W., Jaiswal A. K. Sp3 repression of polymorphic human NRH:quinone oxydoreductase 2 gene promoter. Free Rad. Biol. Med. 2004; 37: 1231–1243
   PubMedGoogle Scholar
• Zammit G., Roth T., Erman M., Sainati S., Weigand S., Zhang J. Double‐blind, placebo‐controlled polysomnography and outpatient trial to evaluate the efficacy and safety of Ramelteon in adult patients with chronic insomnia. Sleep 2005; 28(abst.supp.)A228–A229
   Google Scholar
• Zemlan F. P., Mulchahey J. J., Scharf M. B., Mayleben D. W., Rosenberg R., Lankford A. The efficacy and safety of the melatonin agonist beta‐methyl‐6‐chloromelatonin in primary insomnia: a randomized, placebo‐controlled, crossover clinical trial. J. Clin. Psychiatry 2005; 66: 384–390
   PubMed Web of Science ®Google Scholar